DGII Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Revenue: Decreased 8.3% to $44.9 million, with procedure revenue down 13.2% to $31.3 million, impacted by a $1.7 million revenue loss due to a voluntary product recall.
Dietary Supplement Revenue: Grew 19.1% to $11.0 million, driven by e-commerce growth.
Gross Profit Margin: Fell to 68.9% from 74.3%, primarily due to $1.1 million in costs related to the recall.
Net Income: Reported at $2.7 million, down from $15.8 million year-over-year; diluted EPS decreased to $0.06 from $0.37.
Adjusted EBITDA: Decreased to $8.7 million with a margin of 19.4%.
Cash Flow from Operations: $3.9 million; cash and cash equivalents stood at $5.3 million.

2. Strategic Updates and Business Highlights

Expanded the sales team from over 90 to approximately 120 personnel, hiring over 25 new sales reps in Q1.
Trained more than 200 new practitioners, a 16.5% increase from the previous year, indicating strong interest in hormone optimization and wellness solutions.
Focused on maximizing value from existing top-tier clinics and enhancing commercial capabilities to support practitioners and patients.

3. Forward Guidance and Outlook

Maintained 2026 revenue guidance of over $190 million and adjusted EBITDA of greater than $38 million.
Anticipated return to growth in procedure revenue in the second half of 2026, although first-half growth is expected to be lower due to the recall's impact.
Dietary supplement revenue is projected to grow at a mid- to high single-digit rate.

4. Bad News, Challenges, or Points of Concern

The voluntary recall of hormone pellets created a significant headwind, leading to lower procedure volumes and increased operational costs.
The recall's impact is expected to continue into Q2, affecting sales force productivity and overall revenue.
Gross margin pressures due to reliance on third-party suppliers and the need to allocate inventory to manage supply constraints.
Clinic attrition remains a concern, although management indicated stabilization in attrition rates.

5. Notable Q&A Insights

Management acknowledged challenges with supply constraints and the ongoing impact of the recall, but expressed optimism about returning to normal inventory levels soon.
Positive signs were noted in daily volumes prior to the recall, suggesting potential pent-up demand.
The sales force's expansion was seen as a key factor for future growth, with expectations that new hires will contribute positively once supply issues are resolved.
There was no significant clinic attrition reported as a result of the recall, but management remains cautious about patient retention.

Overall, while DGII faced significant challenges in Q1 2026 due to a product recall, management remains optimistic about the long-term growth trajectory and is actively working to resolve supply issues and enhance sales capabilities.

DGII — Digi International Inc.